BridgeBio Pharma (BBIO) Liabilities and Shareholders Equity (2018 - 2026)

BridgeBio Pharma has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $1.4 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 55.5% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 34.51% YoY) and the FY2025 annual result came in at $936.0 million, up 1.82% from the prior year.
• Liabilities and Shareholders Equity improved to $1.4 billion in Q1 2026 per BBIO's latest filing, from $936.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.4 billion in Q1 2026 and troughed at $503.7 million in Q2 2023.
• A 5-year average of $814.9 million and a median of $813.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 41.59% in 2023, then soared 68.26% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $623.0 million in 2022, then retreated by 12.3% to $546.4 million in 2023, then jumped by 68.26% to $919.3 million in 2024, then advanced by 1.82% to $936.0 million in 2025, then soared by 46.47% to $1.4 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.4 billion, $936.0 million, and $998.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.